The EGFR-induced NF-κB activation may be attributable to BTK pathways—however this is not currently clear given the molecular mechanism of EGFR induced activation of NF-κB in glioma is currently unclear [48]. This evidence concerns the gene NFKB1 and central nervous system cancer.